Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry

Adriana Plesa,Christophe Roumier,Joris Gutrin,Marie-Virginie Larcher,Marie Balsat, Octavia Cadassou,Fiorenza Barraco,Gaelle Fossard,Amandine Baudouin,Helene Labussiere,Isabelle Tigaud,Sophie Ducastelle,Sandrine Hayette,Pierre Sujobert,Mael Heiblig,Mohamed Elhamri,Xavier Thomas

Leukemia Research（2021）

引用 6|浏览13

暂无评分

摘要

•Our short series confirms the high response rate with CPX-351 in t-AML or MRC-AML.•The high rate of MRD negativity supports prior evidence that CPX-351 contributes to long-term remission.•MFC monitoring was confirmed as a reliable approach to assess response to treatment.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要